Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT05411198
Registration number
NCT05411198
Ethics application status
Date submitted
6/06/2022
Date registered
9/06/2022
Date last updated
7/06/2024
Titles & IDs
Public title
Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma
Query!
Scientific title
A Prospective, Multicenter Clinical Study to Evaluate the Safety and Effectiveness of Ab Externo Implantation of Glaucoma Gel Stent
Query!
Secondary ID [1]
0
0
1924-703-007
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Open-Angle Glaucoma
0
0
Query!
Condition category
Condition code
Eye
0
0
0
0
Query!
Diseases / disorders of the eye
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Devices - XEN45 (Glaucoma Gel Stent)
Experimental: XEN45 (Glaucoma Gel Stent) - Participants will receive XEN45 implanted using an ab externo approach on Day 1.
Treatment: Devices: XEN45 (Glaucoma Gel Stent)
Ab externo implant
Query!
Intervention code [1]
0
0
Treatment: Devices
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants Achieving Effectiveness of XEN45
Query!
Assessment method [1]
0
0
Effectiveness is defined as achieving 20% or more reduction of intraocular pressure (IOP) from baseline and on the same or fewer number of glaucoma medications than at baseline without secondary surgical intervention for IOP (SSII).
Query!
Timepoint [1]
0
0
Month 12
Query!
Eligibility
Key inclusion criteria
- Glaucoma in the study eye.
1. Study eye diagnosed with open-angle glaucoma uncontrolled by medical therapy
2. Study eye that meet at least one of the following criteria:
- Failed one or more incisional intraocular glaucoma surgeries (e.g., glaucoma
filtering surgery or tube shunt) (a minimum of approximately 15 subjects
will be enrolled)
- Failed one or more cilioablative procedures (e.g., cryotherapy, cyclodiode
therapy)
- Have neovascular glaucoma
- Have any other condition (e.g., conjunctival scarring, uveitis) in which a
conventional incisional glaucoma surgery like trabeculectomy would be more
likely to fail than for a person with uncomplicated primary open-angle
glaucoma (OAG).
Note: To allow for a subgroup of participants who only have OAG uncontrolled by
medical therapy (non-refractory glaucoma), a maximum of 10 participants who meet
only criterion a (and not b) will be enrolled.
Query!
Minimum age
45
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- A lack of healthy conjunctiva showing free mobility (free of scarring or evidence of
prior surgery) in the target area.
- Excessive intraoperative bleeding, such that visualization in the study eye is
impaired.
- Any anatomy or finding in the study eye that limits the investigator's ability to
visualize the anterior chamber, angle, or target area of the conjunctiva.
- Other surgical complication that in the opinion of the investigator could impede
proper placement of the Gel Stent.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
22/07/2022
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
15/08/2025
Query!
Actual
Query!
Sample size
Target
65
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
0
0
Eye Surgery Associates /ID# 252207 - East Melbourne
Query!
Recruitment hospital [2]
0
0
Melbourne Eye Specialists /ID# 252353 - Fitzroy
Query!
Recruitment postcode(s) [1]
0
0
3002 - East Melbourne
Query!
Recruitment postcode(s) [2]
0
0
VIC3065 - Fitzroy
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arkansas
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Georgia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Kansas
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Maryland
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Minnesota
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Missouri
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
New York
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Oklahoma
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Pennsylvania
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
South Dakota
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Texas
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Utah
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Virginia
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
AbbVie
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Glaucoma is the second most common cause of blindness in the world, second only to cataracts.
This study will assess how safe and effective a glaucoma gel stent is when implanted using
the ab externo approach. Adverse events and intraocular pressure will be assessed.
XEN45 is an approved device for the treatment of glaucoma implanted using the ab interno
approach (inside the eye). XEN45 implanted using the ab externo approach (outside the eye) is
being studied in this study. Approximately 65 participants aged 45 years or older with
open-angle glaucoma will be enrolled in this study at approximately 22 sites in the United
States.
All participants will receive XEN45 implanted using the ab externo approach on Day 1 and will
be followed for 12 months.
Participants will attend regular visits during the study at a hospital or clinic. The safety
and effect of the gel stent on your glaucoma will be checked by medical assessments and eye
examinations.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT05411198
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
ABBVIE INC.
Query!
Address
0
0
AbbVie
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
ABBVIE CALL CENTER
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
844-663-3742
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT05411198
Download to PDF